Compare Marriott International Inc (MAR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs 10X Genomics Inc — how do they compare? Marriott International Inc trades at $360.95 (market cap $94.16B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: Marriott International Inc is far larger — about 9.4× 10X Genomics Inc's market cap, and Marriott International Inc pays a 0.81% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and 10X Genomics Inc for 92 Days on average.
| MAR | TXG | |
|---|---|---|
Market Cap | $94.16B | $10.07B |
Volume | 996,176 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $97.74 |
52-Week Low | $259.04 | $11.48 |
Typical Hold Time | 164 Days | 92 Days |
Enterprise Value | $111.47B | $9.59B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.50, down 1.32% on the day, with a bullish technical signal from moving averages and support near $354. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%, though the P/E of 36.9 suggests a premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share payable in September 2026. Analyst consensus is a Buy with a $386.71 price target, indicating potential upside.
The outlook for MAR is positive, supported by strong travel demand and strategic partnerships, but risks include high debt levels and sensitivity to economic cycles. With institutional interest mixed and a neutral sentiment from oscillators, the stock offers growth potential tempered by valuation concerns and macroeconomic headwinds.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
